Loading cancer entity…
Loading cancer entity…
Clinical trials
6,745 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,044)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05837052 | A Phase II Trial to Evaluate the Efficiency and Safety of Serplulimab Plus Chemotherapy as Conversion Therapy in NSCLC | recruiting | Phase 2 | 49 | Zhejiang UniversityOTHER | 1 | Jul 17, 2023 | clinicaltrials |
| NCT05940532 | A Trial of Sugemalimab and Chemotherapy in Unresectable Stage III NSCLC | recruiting | Phase 2 | 41 | Hunan Cancer HospitalOTHER | 1 | Jul 11, 2023 | clinicaltrials |
| NCT05913089 |
| A Clinical Study of TQB2450 Injection Combined With Chemotherapy or Anlotinib Hydrochloride Capsule in the Treatment of Non Small Cell Lung Cancer |
| recruiting |
| Phase 2 |
| 58 |
| Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY |
| 1 |
| Jun 29, 2023 |
| clinicaltrials |
| NCT05891080 | Neoadjuvant Therapy With Toripalimab and JS004 Combined With Platinum-based Doublet Chemotherapy for Resectable or Potentially Resectable Stage III Non-small Cell Lung Cancer: A Randomised Controlled, Open-label, Phase 2 Trial | not yet recruiting | Phase 2 | 124 | Shanghai Pulmonary Hospital, Shanghai, ChinaOTHER | 0 | Jun 6, 2023 | clinicaltrials |
| NCT02448992 | Hippocampal-Sparing Prophylactic Cranial Irradiation in Pathologically Nodal Positive Non-Small-Cell Lung Cancer | recruiting | Phase 2 / Phase 3 | 90 | Chang Gung Memorial HospitalOTHER | 1 | May 1, 2023 | clinicaltrials |
| NCT05271916 | First-line Treatment With Dacomitinib Plus Anlotinib for Patients With Advanced NSCLC With EGFR 21L858R Mutations | recruiting | Phase 1 / Phase 2 | 140 | Shanghai Chest HospitalOTHER | 1 | Apr 19, 2023 | clinicaltrials |
| NCT05800340 | Neoadjuvant Immunotherapy in Rare Mutations Localized NSCLC | recruiting | Phase 2 | 30 | Guangdong Provincial People's HospitalOTHER | 1 | Apr 5, 2023 | clinicaltrials |
| NCT05784142 | Chemo-immunotherapy Induction Followed by Hypo-radiotherapy in LA-NSCLC(CHIC)(CHIC) | active not recruiting | Phase 2 | 55 | Jiangsu Cancer Institute & HospitalOTHER | 1 | Mar 24, 2023 | clinicaltrials |
| NCT05778149 | Safety and Efficacy of Aumolertinib Combined With Anlotinib as 1st Line Treatment in Advanced Lung Cancer EGFR Mutation With TP53 Co-Mutation | not yet recruiting | Phase 2 | 47 | Tianjin Medical University Cancer Institute and HospitalOTHER | 0 | Mar 21, 2023 | clinicaltrials |
| NCT05286957 | MRD-guided Adjuvant Tislelizumab and Chemotherapy in Resected Stage IIA-IIIB NSCLC(Seagull) | recruiting | Phase 2 | 60 | The First Affiliated Hospital of Zhengzhou UniversityOTHER | 1 | Mar 17, 2023 | clinicaltrials |
| NCT05733000 | CPI-613 (Devimistat) in Combination With Hydroxychloroquine and 5-fluorouracil or Gemcitabine in Treating Patients With Advanced Chemorefractory Solid Tumors | recruiting | Phase 2 | 94 | Northwestern UniversityOTHER | 1 | Mar 10, 2023 | clinicaltrials |
| NCT05686434 | Osimertinib Therapy After Resection in High-risk Stage I EGFRm NSCLC (OSTAR) | recruiting | Phase 2 | 65 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Jan 17, 2023 | clinicaltrials |
| NCT05597800 | Nivolumab/Ipilimumab and Chemotherapy Combination in Advanced NSCLC Patients With HIV, HBV, HCV and Long Covid Syndrome(LUNGVIR) | not yet recruiting | Phase 2 | 105 | Universita di VeronaOTHER | 1 | Oct 28, 2022 | clinicaltrials |
| NCT05548504 | Heterogeneously Hypofractionated Radiotherapy for Locally Advanced NSCLC(HERAN2) | not yet recruiting | Phase 2 | 182 | Odense University HospitalOTHER | 0 | Sep 21, 2022 | clinicaltrials |
| NCT05334277 | Furmonertinib Monotherapy and Combination Therapy in Advanced EGFR Mutant NSCLC With Uncleared ctDNA(FOCUS-C) | recruiting | Phase 2 | 280 | Sun Yat-sen UniversityOTHER | 1 | Aug 31, 2022 | clinicaltrials |
| NCT04875585 | Trial Exploring Combined Neoadjuvant Therapy With Pembrolizumab/Lenvatinib + Adjuvant Pembrolizumab in Pat. With NSCLC(INNWOP1) | recruiting | Phase 2 | 33 | Medical University InnsbruckOTHER | 1 | Aug 24, 2022 | clinicaltrials |
| NCT05503667 | Neoadjuvant Furmonertinib Plus Bevacizumab or Furmonertinib Monotherapy for Resectable and Potentially Resectable Stage III-IVA EGFR Mutation-Positive Lung Adenocarcinoma | recruiting | Phase 2 | 96 | Shanghai Pulmonary Hospital, Shanghai, ChinaOTHER | 1 | Aug 17, 2022 | clinicaltrials |
| NCT05469022 | Neoadjuvant Lazertinib Therapy in EGFR-Mutation Positive Lung Adenocarcinoma Detected by BALF Liquid Biopsy | recruiting | Phase 2 | 40 | Konkuk University Medical CenterOTHER | 1 | Jul 21, 2022 | clinicaltrials |
| NCT03836352 | Study of an Immunotherapeutic, DPX-Survivac, in Combination With Low Dose Cyclophosphamide & Pembrolizumab, in Subjects With Selected Advanced & Recurrent Solid Tumors | active not recruiting | Phase 2 | 184 | ImmunoVaccine Technologies, Inc. (IMV Inc.)INDUSTRY | 2 | Mar 31, 2022 | clinicaltrials |
| NCT05186506 | A Study Comparing Ensatinib Versus Platinum-Based Chemotherapy as Adjuvant Treatment for Stage II-IIIA ALK -Positive Non-Small Cell Lung Cancer | not yet recruiting | Phase 2 | 152 | Sichuan UniversityOTHER | 0 | Jan 11, 2022 | clinicaltrials |
| NCT05132985 | Neoadjuvant Icotinib With Chemotherapy for Epidermal Growth Factor Receptor(EGFR)-Mutated Resectable Lung Adenocarcinoma | not yet recruiting | Phase 2 | 45 | Liaoning Cancer Hospital & InstituteOTHER | 1 | Dec 10, 2021 | clinicaltrials |
| NCT05104788 | A Study of Icotinib With Chemotherapy as Neoadjuvant Therapy for Patients With EGFRm Positive Resectable Non-Small Cell Lung Cancer(NeoIpower) | recruiting | Phase 2 | 27 | Peking University Cancer Hospital & InstituteOTHER | 1 | Nov 3, 2021 | clinicaltrials |
| NCT04846634 | Penpulimab-based Combination Neoadjuvant/Adjuvant Therapy for Patients With Resectable Locally Advanced Non-small Cell Lung Cancer: a Phase II Clinical Study (ALTER-L043)(ALTER-L043) | not yet recruiting | Phase 2 | 90 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Apr 15, 2021 | clinicaltrials |
| NCT04153734 | Pembrolizumab + Platinum Doublets Without Radiation for Programmed Death-ligand 1 (PD-L1) ≥50% Locally Advanced NSCLC(Evolution) | not yet recruiting | Phase 2 | 21 | Kobe Minimally Invasive Cancer CenterOTHER | 0 | Nov 6, 2019 | clinicaltrials |
| NCT03392233 | Stereotactic Body Radiation Therapy for Spinal Metastases in Favorite Tumors | recruiting | Phase 2 | 100 | RenJi HospitalOTHER | 1 | Jan 5, 2018 | clinicaltrials |
| NCT03351842 | Surgery With or Without Chemotherapy for Stage I NSCLC With Micropapillary Component ≥ 20% | recruiting | Phase 2 | 460 | Shanghai Pulmonary Hospital, Shanghai, ChinaOTHER | 1 | Dec 19, 2017 | clinicaltrials |
| NCT02493582 | The Study of Apatinib Plus CIK as the Third Line Therapy for Advanced Lung Adenocarcinoma Patients With Wild-Type EGFR | active not recruiting | Phase 2 | 400 | The First People's Hospital of ChangzhouOTHER | 0 | Feb 5, 2016 | clinicaltrials |
Data updated 23 days agoSource updated Jul 17, 2023source: clinicaltrials